tm
Seeing Is Believing
tm
Seeing Is Believing
Healthcare - Sector
BIIB is currently covered by 28 analysts with an average price target of $253.74. This is a potential upside of $58.59 (30.02%) from yesterday's end of day stock price of $195.15.
Biogen's activity chart (see below) currently has 774 price targets and 669 ratings on display. The stock rating distribution of BIIB is 77.71% BUY and 22.29% HOLD.
Analysts average stock forecasts to be materialized ratio is 66.87% with an average time for these price targets to be met of 233.87 days.
Highest price target for BIIB is $373, Lowest price target is $215, average price target is $253.74.
Most recent stock forecast was given by CARTER GOULD from BARCLAYS on 04-Apr-2024. First documented stock forecast 09-Sep-2010.
BiogenĀ is focused on the discovery, development, manufacturing innovative therapies for the treatment of neurological and neurodegenerative diseases.
Biogen offers a diverse portfolio of therapies targeting various neurological conditions.
For multiple sclerosis (MS), the company provides products such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA, which aim to manage and alleviate the symptoms of this chronic autoimmune disease.
Biogen’s SPINRAZA is a groundbreaking therapy for spinal muscular atrophy (SMA), a genetic neuromuscular disorder that affects muscle movement. The company’s innovative treatment, ADUHELM, addresses Alzheimer’s disease, a progressive neurodegenerative disorder characterized by cognitive decline.
In addition to MS, SMA, and Alzheimer’s disease, Biogen’s product lineup encompasses various therapeutic areas. The company offers FUMADERM to treat plaque psoriasis, a chronic skin condition. BENEPALI, IMRALDI, and FLIXABI are biosimilars developed by Biogen, referencing well-established therapies for conditions like rheumatoid arthritis and certain types of cancer.
Furthermore, Biogen delivers therapies like RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and glofitamab to address a range of disorders, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, and other immunological and neurovascular conditions.
Biogen’s headquarters are located in Cambridge, Massachusetts, since it was founded in 1978.
Currently out of the existing stock ratings of BIIB, 122 are a BUY (77.71%), 35 are a HOLD (22.29%).
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
215
$10.05 (4.90%)
294
16 days ago
19/22 (86.36%)
$9.7 (4.72%)
231
Buy
340
$135.05 (65.89%)
340
26 days ago
17/34 (50%)
$123.31 (56.91%)
342
Buy
277
$72.05 (35.15%)
335
1 months 29 days ago
24/33 (72.73%)
$54.52 (24.51%)
126
Buy
311
$106.05 (51.74%)
311
2 months ago
3/8 (37.5%)
$91.79 (41.87%)
747
Buy
305
$100.05 (48.82%)
310
2 months ago
14/23 (60.87%)
$85.79 (39.14%)
228
What is BIIB (Biogen) average time for price targets to be met?
Which analyst has the current highest performing score on BIIB (Biogen) with a proven track record?
Which analyst has the most public recommendations on BIIB (Biogen)?
Which analyst is the currently most bullish on BIIB (Biogen)?
Which analyst is the currently most reserved on BIIB (Biogen)?
